These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 3652060

  • 1. Weekly cyclophosphamide and alternate-day prednisone: an effective secondary therapy in multiple myeloma.
    Wilson K, Shelley W, Belch A, Brandes L, Bergsagel D, Klimo P, White D, Willan A.
    Cancer Treat Rep; 1987 Oct; 71(10):981-2. PubMed ID: 3652060
    [Abstract] [Full Text] [Related]

  • 2. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM, Harrington DP, Abramson N, Kyle RA, Knospe W, Glick JH.
    Cancer; 1997 Apr 15; 79(8):1561-7. PubMed ID: 9118039
    [Abstract] [Full Text] [Related]

  • 3. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM, Leong T, Lenhard RE, Greipp PR, Kay NE, Van Ness B, Keimowitz RM, Kyle RA.
    Cancer; 1999 Sep 15; 86(6):957-68. PubMed ID: 10491521
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
    Cavo M, Benni M, Ronconi S, Fiacchini M, Gozzetti A, Zamagni E, Cellini C, Tosi P, Baccarani M, Tura S, Writing Committee of the "Bologna 90" Clinical Trial.
    Haematologica; 2002 Sep 15; 87(9):934-42. PubMed ID: 12217805
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Progress in the treatment of multiple myeloma].
    Wada M, Mizoguchi H.
    Gan To Kagaku Ryoho; 1997 Jul 15; 24(9):1079-88. PubMed ID: 9239160
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma.
    Hernández JM, García-Sanz R, Golvano E, Bladé J, Fernandez-Calvo J, Trujillo J, Soler JA, Gardella S, Carbonell F, Mateo G, San Miguel JF.
    Br J Haematol; 2004 Oct 15; 127(2):159-64. PubMed ID: 15461621
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone.
    Cavagnaro F, Lein JM, Pavlovsky S, Becherini JO, Pileggi JE, Micheo EQ, Jait C, Musso A, Suárez A, Pizzolato M.
    Cancer Treat Rep; 1980 Jan 15; 64(1):73-9. PubMed ID: 6991106
    [Abstract] [Full Text] [Related]

  • 14. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
    Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC.
    J Clin Oncol; 2006 Feb 20; 24(6):929-36. PubMed ID: 16432076
    [Abstract] [Full Text] [Related]

  • 15. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D, Bosković D, Radosević N, Elezović I, Tomin D, Gotić M, Antunović P.
    Srp Arh Celok Lek; 1996 Feb 20; 124(11-12):292-6. PubMed ID: 9132962
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Addition of cisplatin and bleomycin to vincristine-carmustine-doxorubicin-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
    Bonnet JD, Alexanian R, Salmon SE, Haut A, Dixon DO.
    Cancer Treat Rep; 1984 Mar 20; 68(3):481-5. PubMed ID: 6200220
    [Abstract] [Full Text] [Related]

  • 19. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
    Anagnostopoulos A, Aleman A, Ayers G, Donato M, Champlin R, Weber D, Alexanian R, Giralt S.
    Cancer; 2004 Jun 15; 100(12):2607-12. PubMed ID: 15197803
    [Abstract] [Full Text] [Related]

  • 20. Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: results and cost analysis.
    Annibali O, Petrucci MT, Martini V, Tirindelli MC, Levi A, Fossati C, Del Bianco P, Mandelli F, Foa R, Avvisati G.
    Cancer; 2005 Feb 01; 103(3):582-7. PubMed ID: 15611977
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.